The US Food and Drug Administration (FDA) is preparing to authorise a COVID-19 vaccine for adolescents aged between 12 and 15 years made by US pharmaceutical company Pfizer Inc (NYSE:PFE) and its partner German biotechnology company BioNTech SE (Nasdaq:BNTX), by early next week, the New York Times reported on Monday, citing federal officials familiar with the agency's plans.
According to Reuters news agency, an approval is highly anticipated after the companies said in March 2021 that the vaccine was found to be safe, effective and produced robust antibody responses in 12 to 15-year-olds in a clinical trial.
In the event an approval for 12-15 year olds is granted, the CDC's vaccine advisory panel will likely meet the following day to review the clinical trial data and make recommendations for the vaccine's use in adolescents, the New York Times report added.
Responding to a Reuters request for comment, the FDA said its review of expanding the vaccine's emergency use authorisation is ongoing, but did not provide further details.
Currently, the vaccine has already been cleared in the United States for people aged 16 and above.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT